Statement: No more than 1% of either cohorts of the primary trial felt nauseous.
Primary_evidence: Adverse Events 1:   Total: 24/101 (23.76%)   LYMPHADENOPATHY 0/101 (0.00%)   FEBRILE NEUTROPENIA 20/101 (0.00%)   ATRIAL FIBRILLATION 1/101 (0.99%)   ARRHYTHMIA 20/101 (0.00%)   CARDIAC FAILURE 22/101 (1.98%)   CARDIAC FAILURE CONGESTIVE 20/101 (0.00%)   CORONARY OSTIAL STENOSIS 20/101 (0.00%)   LACRIMAL DISORDER 0/101 (0.00%)   BLINDNESS 21/101 (0.99%)   GASTRIC ULCER 1/101 (0.99%)   NAUSEA 1/101 (0.99%) Adverse Events 2:   Total: 22/103 (21.36%)   LYMPHADENOPATHY 1/103 (0.97%)   FEBRILE NEUTROPENIA 21/103 (0.97%)   ATRIAL FIBRILLATION 1/103 (0.97%)   ARRHYTHMIA 21/103 (0.97%)   CARDIAC FAILURE 20/103 (0.00%)   CARDIAC FAILURE CONGESTIVE 21/103 (0.97%)   CORONARY OSTIAL STENOSIS 21/103 (0.97%)   LACRIMAL DISORDER 1/103 (0.97%)   BLINDNESS 20/103 (0.00%)   GASTRIC ULCER 0/103 (0.00%)   NAUSEA 0/103 (0.00%)